Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
- 12 December 2023
- journal article
- review article
- Published by Wiley in Advanced Materials
- Vol. 36 (13) , e2300665
Abstract
Clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) gene‐editing technology shows promise for manipulating single or multiple tumor‐associated genes and engineering immune cells to treat cancers. Currently, most gene‐editing strategies rely on viral delivery; yet, while being efficient, many limitations, mainly from safety and packaging capacity considerations, hinder the use of viral CRISPR vectors in cancer therapy. In contrast, recent advances in non‐viral CRISPR/Cas9 nanoformulations have paved the way for better cancer gene editing, as these nanoformulations can be engineered to improve safety, efficiency, and specificity through optimizing the packaging capacity, pharmacokinetics, and targetability. In this review, the advance in non‐viral CRISPR delivery is highlighted, and there is a discussion on how these approaches can be potentially used to treat cancers in addressing the aforementioned limitations, followed by the perspectives in designing a proper CRISPR/Cas9‐based cancer nanomedicine system with translational potential.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFC2400600, 2019YFA0111300)
- National Natural Science Foundation of China (52373166, 22277155, 52022095, 52073280, 51903256, 21907113, 51873207)
- Guangdong Provincial Pearl River Talents Program (2019QN01Y131)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2019230)
- China Primary Health Care Foundation (2022‐003)
This publication has 278 references indexed in Scilit:
- Gene Therapy That WorksScience, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Physical and Chemical Strategies for Therapeutic Delivery by Using Polymeric NanoparticlesPharmacological Reviews, 2012
- Circumventing Cancer Drug Resistance in the Era of Personalized MedicineCancer Discovery, 2012
- Nanoparticle Hydrophobicity Dictates Immune ResponseJournal of the American Chemical Society, 2012
- In vivo genome editing restores haemostasis in a mouse model of haemophiliaNature, 2011
- Engineering lymphocyte subsets: tools, trials and tribulationsNature Reviews Immunology, 2009
- Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer ModelCell, 2009
- Charge‐Conversion Ternary Polyplex with Endosome Disruption Moiety: A Technique for Efficient and Safe Gene DeliveryAngewandte Chemie International Edition, 2008
- The Hallmarks of CancerCell, 2000